ARS Pharmaceuticals, Inc. (SPRY)
NASDAQ: SPRY · Real-Time Price · USD
8.17
-0.08 (-0.97%)
At close: Mar 20, 2026, 4:00 PM EDT
8.20
+0.03 (0.37%)
Pre-market: Mar 23, 2026, 7:29 AM EDT
ARS Pharmaceuticals Employees
As of December 31, 2025, ARS Pharmaceuticals had 163 total employees, including 158 full-time and 5 part-time employees. The number of employees increased by 3 or 1.88% compared to the previous year.
Employees
163
Change
3
Growth
1.88%
Revenue / Employee
$517,043
Profits / Employee
-$1,050,908
Market Cap
811.26M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Dec 31, 2025 | 163 | 3 | 1.88% | 158 | 5 |
| Sep 30, 2025 | 167 | 16 | 10.60% | 162 | 5 |
| Jun 30, 2025 | 167 | 139 | 496.43% | 162 | 5 |
| Dec 31, 2024 | 160 | 134 | 515.38% | 155 | 5 |
| Sep 30, 2024 | 151 | 124 | 459.26% | 146 | 5 |
| Jun 30, 2024 | 28 | -6 | -17.65% | 23 | 5 |
| Mar 31, 2024 | 26 | -5 | -16.13% | 24 | 2 |
| Dec 31, 2023 | 26 | 6 | 30.00% | 24 | 2 |
| Sep 30, 2023 | 27 | 16 | 145.45% | 24 | 3 |
| Jun 30, 2023 | 34 | 23 | 209.09% | 29 | 5 |
| Mar 31, 2023 | 31 | 22 | 244.44% | 27 | 4 |
| Dec 31, 2022 | 20 | 11 | 122.22% | 17 | 3 |
| Jun 30, 2022 | 11 | - | - | 9 | 2 |
| Dec 31, 2021 | 9 | - | - | 9 | 0 |
Related Stocks
| Company Name | Employees |
|---|---|
| UroGen Pharma | 291 |
| Omeros | 202 |
| Sana Biotechnology | 142 |
| Adlai Nortye | 123 |
| Cullinan Therapeutics | 109 |
| Janux Therapeutics | 109 |
| Inventiva | 84 |
| Arbutus Biopharma | 44 |
SPRY News
- 11 days ago - ARS Pharmaceuticals: Neffy's Slow Launch, No Guidance For 2026 Keep Me On Sidelines - Seeking Alpha
- 13 days ago - ARS Pharmaceuticals, Inc. (SPRY) Q4 2025 Earnings Call Transcript - Seeking Alpha
- 14 days ago - ARS Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Updates on neffy® (epinephrine nasal spray) Commercialization - GlobeNewsWire
- 27 days ago - ARS Pharmaceuticals Announces Conference Call and Webcast for its Fourth Quarter and Full Year 2025 Financial Results and Participation at Upcoming Conferences - GlobeNewsWire
- 5 weeks ago - ARS Pharmaceuticals: Climbing Neffy Sales And Global Expansion Could Re-Rate The Stock - Seeking Alpha
- 5 weeks ago - ARS Pharmaceuticals to Showcase Scientific Innovation and Robust Clinical Data on neffy® (epinephrine nasal spray) at 2026 American Academy of Allergy, Asthma and Immunology (AAAAI) Annual Scientific Meeting - GlobeNewsWire
- 6 weeks ago - EURneffy® 1 mg (adrenaline nasal spray) Recommended for Approval in the EU for Emergency Treatment of Type 1 Allergic Reactions, including Anaphylaxis in Children Weighing ≥15 kg to - GlobeNewsWire
- 2 months ago - California K-12 Schools Now Eligible for neffyinSchools Program, Offering Needle-Free Epinephrine at No Cost for Emergency Use - GlobeNewsWire